


Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 11/01/2021
Policy Number: PA.CP.PHAR.321	Effective Date: 01/2020 Revision Date: 10/2021
Policy Name: Panitumumab (Vectibix)	
<p>Type of Submission – <u>Check all that apply</u>:</p> <p> <input type="checkbox"/> New Policy <input checked="" type="checkbox"/> Revised Policy* <input type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> </p>	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any changes or clarifying information for the policy below:</p> <p>4Q 2021 annual review: added that combination treatment with Vectibix and Braftovi is for advanced or metastatic disease per NCCN Compendium; for Vectibix prescribed as a single agent or in combination with irinotecan, added the option of previous oxaliplatin-based therapy without irinotecan or irinotecan-based therapy without oxaliplatin per NCCN Compendium; references reviewed and updated.</p>	
<p>Name of Authorized Individual (Please type or print):</p> <p>Venkateswara R. Davuluri, MD</p>	<p>Signature of Authorized Individual:</p> 

Clinical Policy: Panitumumab (Vectibix)

Reference Number: PA.CP.PHAR.321

Effective Date: 01.18

Last Review Date: 10/2021

[Coding Implications](#)

[Revision Log](#)

Description

Panitumumab (Vectibix[®]) is an epidermal growth factor receptor (EGFR) antagonist.

FDA Approved Indication(s)

Vectibix is indicated for the treatment of patients with wild-type *RAS* (defined as wild-type in both *KRAS* and *NRAS* as determined by an FDA-approved test for this use) metastatic colorectal cancer (CRC):

- In combination with FOLFOX for first-line treatment
- As monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy

Limitation(s) of use: Vectibix is not indicated for the treatment of patients with *RAS*-mutant metastatic CRC or for whom *RAS* mutation status is unknown.

Policy/Criteria

It is the policy of health plans affiliated with Pennsylvania Health and Wellness[®] that Vectibix is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Colorectal Cancer (must meet all):

1. Diagnosis of colorectal cancer (CRC);
2. Prescribed by or in consultation with an oncologist;
3. Age \geq 18 years;
4. Disease is one of the following (a or b):
 - a. Wild-type *RAS* (defined as wild-type in both *KRAS* and *NRAS*);
 - b. BRAF wild-type;
5. One of the following (a, b, c, or d)*:
 - a. Request is for first-line treatment: Prescribed in combination with FOLFOX or FOLFIRI (off-label);
 - b. Previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (e.g., FOLFOXIRI), oxaliplatin-based therapy without irinotecan, or irinotecan-based therapy without oxaliplatin: prescribed as a single agent or in combination with irinotecan (off-label);
 - c. Previous treatment with an oxaliplatin containing regimen (e.g., FOLFOX, CapeOx): prescribed in combination with FOLFIRI or irinotecan (off-label);
 - d. Previous treatment with an oxaliplatin containing regimen (e.g., FOLFOX, CapeOx), fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (e.g., FOLFOXIRI), without irinotecan or oxaliplatin followed by FOLFOX, or member is intolerant to irinotecan or oxaliplatin: prescribed in combination with Braftovi[®] if BRAF V600E mutation positive for advanced or metastatic disease (off-label);

**Prior authorization may be required.*

6. Request meets one of the following (a or b):*
 - a. Dose does not exceed 6 mg/kg every 14 days;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months

B. Other diagnoses/indications: Refer to PA.CP.PMN.53

II. Continued Approval

A. Colorectal Cancer (must meet all):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met all initial approval criteria; or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 6 mg/kg every 14 days;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit and documentation supports positive response to therapy; or the Continuity of Care policy (PA.LTSS.PHAR.01) applies; or
2. Refer to PA.CP.PMN.53

III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CRC: colorectal cancer

EGFR: epidermal growth factor receptor

FDA: Food and Drug Administration

FOLFIRI: fluorouracil, leucovorin,
irinotecan

FOLFOX: fluorouracil, leucovorin,
oxaliplatin

KRAS: Kirsten rat sarcoma 2 viral
oncogene homologue

CRC: colorectal cancer

FOLFOXIRI: fluorouracil, leucovorin,
oxaliplatin, irinotecan

NRAS: neuroblastoma RAS viral oncogene
homologue

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Modified FOLFOX 6	Day 1: oxaliplatin 85 mg/m ² IV Day 1: Folinic acid 400 mg/m ² IV Days 1–3: 5-FU 400 mg/m ² IV bolus on day 1, then 1,200 mg/m ² /day × 2 days (total 2,400 mg/m ² over 46–48 hours) IV continuous infusion Repeat cycle every 2 weeks.	See dosing regimen
CapeOX	Day 1: Oxaliplatin 130 mg/m ² IV Days 1–14: Capecitabine 1,000 mg/m ² PO BID Repeat cycle every 3 weeks.	See dosing regimen
FOLFIRI	Day 1: Irinotecan 180 mg/m ² IV Day 1: Leucovorin 400 mg/m ² IV Day 1: Flurouracil 400 mg/m ² IV followed by 2,400 mg/m ² continuous IV over 46 hours Repeat cycle every 14 days.	See dosing regimen
FOLFOXIRI	Day 1: Irinotecan 165 mg/m ² IV, oxaliplatin 85 mg/m ² IV, leucovorin 400 mg/m ² IV, flurouracil 1,600 mg/m ² continuous IV for 2 days (total 3,200 mg/m ²) Repeat cycle every 2 weeks.	See dosing regimen
Braftovi (Encorafenib)	300 mg PO once daily in combination with panitumumab (6 mg/kg IV every 14 days) until disease progression or unacceptable toxicity.	450 mg/day.

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): dermatologic toxicity

IV. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CRC	6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) every 14 days	6 mg/kg

V. Product Availability

Single-dose vial for injection: 100 mg/5 mL, 400 mg/20 mL

VI. References

1. Vectibix Prescribing Information. Thousand Oaks, CA: Amgen, Inc.; June 2017. Available at <https://www.vectibix.com/>. Accessed August 9, 2021.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed August 9, 2021.

3. National Comprehensive Cancer Network. Colon Cancer Version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed August 9, 2021.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9303	Injection, panitumumab, 10 mg

Reviews, Revisions, and Approvals	Date	Approval Date
4Q 2018 annual review: no significant changes; summarized NCCN and FDA-approved uses for improved clarity; added specialist involvement in care; references reviewed and updated.	07/18	
4Q 2019 annual review: No changes per Statewide PDL implementation 01-01-2020	10/30/19	
4Q 2020 annual review: added BRAF disease wild-type and for treatment in combination with Braftovi if BRAF V600E mutation position to colorectal indication as per NCCN 2A off label indication; references reviewed and updated.	08/20	11/20
4Q 2021 annual review: added that combination treatment with Vectibix and Braftovi is for advanced or metastatic disease per NCCN Compendium; for Vectibix prescribed as a single agent or in combination with irinotecan, added the option of previous oxaliplatin-based therapy without irinotecan or irinotecan-based therapy without oxaliplatin per NCCN Compendium; references reviewed and updated.	10/2021	